Not Signed In - Ube Industries, Santen Pharmaceutical To Co-develop Rho-kinase Inhibitor For Glaucoma And Ocular Hypertension Treatment
Mon, 15 May 2006 06:00 AM EST
... Tokyo - On May 9, Ube Industries and Santen Pharmaceutical jointly announced that they have basically agreed to develop DE-104, a compound that inhibits the activity of Rho-kinase (ROCK). Through collaboration, the two companies aim to develop an ophthalmic solution for treating glaucoma and ocular hypertension. [click link for full article] ...
Related Topics
- Glaucoma
- Pulmonary Hypertension
- Hypertension
- Histoplasmosis
- Intracranial Hypertension
- Rho (D) Immune Globulin
- Confusion and changes in mental status may develop if the condition is not treated.
- EGFR
- Trypsin
- Aldosterone
- Melanoma
- Pyruvate kinase deficiency
- Eye Diseases
- Drug Information
- Sarcoidosis
- Agenesis of the Corpus Callosum
- Rosacea
- Preeclampsia
- Treatment
- Migraine
email this page
print this page
bookmark this page
feedback on this page
